MdxHealth SA, a multinational healthcare company, has announced that MediNcrease Health Plans, a national provider network in the US, has signed a contract to make ConfirmMDx for prostate cancer and SelectMDx for prostate cancer available to 5.5 million covered lives through its clients and payers.
"The ongoing US adoption of ConfirmMDx and SelectMDx for Prostate Cancer reinforces the value of the tests to improve patient outcomes while reducing healthcare costs," said Dr. Jan Groen, chief executive officer of MDxHealth.
"We are thrilled to welcome MDxHealth, a global leader in the diagnosis and treatment of cancer, to the MediNcrease Provider Network," said Linda Plaster, chief executive officer of MediNcrease Health Plans. "This exciting relationship affirms continued commitment to our specialty provider network expansion."